PRNewsWire
28 Sept 2025, 14:00 UTC · 51w ago
Verdict
Headline takes no side. We score UNCY −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) for Unicycive's oxylanthanum carbonate (OLC) NDA due to cGMP compliance deficiencies at a third-party subcontractor.
More negative than 99% of claims this week
A class action lawsuit has been filed against Unicycive Therapeutics and its officers alleging materially false statements regarding manufacturing compliance and regulatory prospects.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit following a significant drop in stock price due to FDA deficiencies and a Complete Response Letter for its OLC NDA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
+19.7%
Price is moving against the score
$4.81 vs $4.02 close before publication (Sep 26) · not market-adjusted
UNCY chart →
